Table 4 |
|||
|
Ranking of subnetworks based on their best new interactions and number of dimensions. The interaction level of known interactions was determined by the arithmetic average of all similarities returned by the vector space model. |
|||
|
Subnetwork |
Dimensional Space |
New Interaction |
Level of Interaction |
|
|
|||
|
6 |
gene target |
androgen receptor adrenaline |
0.9757 |
|
2 |
disease gene |
HIV transforming growth factor, beta 1 |
0.9738 |
|
5 |
drug target |
verapamil cyclooxygenase 2 |
0.9597 |
|
1 |
disease drug |
erectile dysfunction divalproex |
0.9470 |
|
3 |
disease target |
arrhythmia cyclic-gmp phosphodiesterase |
0.9272 |
|
4 |
drug gene |
ciclosporin androgen receptor |
0.8211 |
|
|
|||
|
8 |
disease drug target |
alzheimer dementia acetylsalicylic acid adrenaline |
0.8807 |
|
10 |
drug gene target |
acarbose apolipoprotein a 1 lymphotoxin |
0.8723 |
|
9 |
disease gene target |
parkinson disease apolipoprotein e choline acetylase |
0.8695 |
|
7 |
disease drug gene |
gout hydrochlorothiazide endothelin 1 |
0.8357 |
|
|
|||
|
11 |
disease drug gene target |
breast adenocarcinoma tamoxifen ppar-gamma hmg-coa reductase |
0.7826 |
|
|
|||
|
Maciel et al. BMC Genomics 2011 12(Suppl 4):S1 doi:10.1186/1471-2164-12-S4-S1 |
|||
